Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 CAT Study of Inhaled Aztreonam in Cystic Fibrosis with Chronic Pseudomonas aeruginosa Infection
2015-000398-11Phase 3
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) and pulmonary infection comparing AZLI + TIS CAT regimen with Placebo + TIS CAT regimen (2 arms). Primary endpoint: Rate of protocol-defined exacerbations from Day 1 through Week 24.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)pulmonary infection
Beyond the preview
Go deeper on 2015-000398-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000398-11.